BioTelemetry Company Profile (NASDAQ:BEAT)

About BioTelemetry (NASDAQ:BEAT)

BioTelemetry logoBioTelemetry, Inc. (BioTelemetry), formerly CardioNet, Inc., provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment's principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Company's research services focuses on providing cardiac safety monitoring services for drug and medical treatment trials in a research environment. In August 2012, the Company completed the acquisition of Cardiocore Lab, Inc. (Cardiocore).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BEAT
  • CUSIP: N/A
  • Web:
  • Market Cap: $823.83 million
  • Outstanding Shares: 28,655,000
Average Prices:
  • 50 Day Moving Avg: $30.08
  • 200 Day Moving Avg: $25.02
  • 52 Week Range: $14.72 - $34.00
  • Trailing P/E Ratio: 17.96
  • Foreward P/E Ratio: 24.78
  • P/E Growth: 1.45
Sales & Book Value:
  • Annual Revenue: $205.49 million
  • Price / Sales: 4.01
  • Book Value: $4.99 per share
  • Price / Book: 5.76
  • EBIDTA: $39.1 million
  • Net Margins: 7.58%
  • Return on Equity: 26.70%
  • Return on Assets: 15.81%
  • Debt-to-Equity Ratio: 0.26%
  • Current Ratio: 1.60%
  • Quick Ratio: 1.51%
  • Average Volume: 508,848 shs.
  • Beta: 0.9
  • Short Ratio: 1.79

Frequently Asked Questions for BioTelemetry (NASDAQ:BEAT)

What is BioTelemetry's stock symbol?

BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT."

How were BioTelemetry's earnings last quarter?

BioTelemetry, Inc. (NASDAQ:BEAT) announced its earnings results on Wednesday, May, 3rd. The company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.02. The company earned $55.88 million during the quarter, compared to analyst estimates of $55.11 million. BioTelemetry had a net margin of 7.58% and a return on equity of 26.70%. View BioTelemetry's Earnings History.

When will BioTelemetry make its next earnings announcement?

BioTelemetry is scheduled to release their next quarterly earnings announcement on Monday, July, 31st 2017. View Earnings Estimates for BioTelemetry.

Where is BioTelemetry's stock going? Where will BioTelemetry's stock price be in 2017?

5 brokers have issued 12 month price objectives for BioTelemetry's stock. Their predictions range from $24.00 to $37.00. On average, they anticipate BioTelemetry's share price to reach $28.25 in the next year. View Analyst Ratings for BioTelemetry.

Who are some of BioTelemetry's key competitors?

Who owns BioTelemetry stock?

BioTelemetry's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.37%), Vanguard Group Inc. (5.90%), Dimensional Fund Advisors LP (5.08%), Renaissance Technologies LLC (4.40%), Wellington Management Group LLP (3.56%) and Cannell Capital LLC (3.21%). Company insiders that own BioTelemetry stock include Daniel Wisniewski, Fred Broadway, George Hrenko, Heather C Getz, Joseph H Capper, Peter Ferola and Robert J Rubin. View Institutional Ownership Trends for BioTelemetry.

Who sold BioTelemetry stock? Who is selling BioTelemetry stock?

BioTelemetry's stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Kalmar Investments Inc. DE, Cortina Asset Management LLC, Wells Fargo & Company MN, Royce & Associates LP, Systematic Financial Management LP, Icon Advisers Inc. Co. and AQR Capital Management LLC. Company insiders that have sold BioTelemetry stock in the last year include Daniel Wisniewski, Fred Broadway, George Hrenko, Heather C Getz, Joseph H Capper, Peter Ferola and Robert J Rubin. View Insider Buying and Selling for BioTelemetry.

Who bought BioTelemetry stock? Who is buying BioTelemetry stock?

BioTelemetry's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Wellington Management Group LLP, Vanguard Group Inc., Renaissance Technologies LLC, Driehaus Capital Management LLC, Russell Investments Group Ltd., Virginia Retirement Systems ET AL and Bogle Investment Management L P DE. View Insider Buying and Selling for BioTelemetry.

How do I buy BioTelemetry stock?

Shares of BioTelemetry can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of BioTelemetry stock cost?

One share of BioTelemetry stock can currently be purchased for approximately $28.75.

Analyst Ratings

Consensus Ratings for BioTelemetry (NASDAQ:BEAT) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $28.25 (1.74% downside)

Analysts' Ratings History for BioTelemetry (NASDAQ:BEAT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/11/2017Dougherty & CoBoost Price TargetBuy -> Buy$30.00 -> $37.00LowView Rating Details
12/13/2016GabelliReiterated RatingBuyN/AView Rating Details
10/5/2016Lake Street CapitalReiterated RatingBuy$24.00N/AView Rating Details
9/13/2016SidotiInitiated CoverageBuy$27.00N/AView Rating Details
8/3/2016Benchmark Co.Boost Price TargetBuy$20.00 -> $25.00N/AView Rating Details
(Data available from 5/28/2015 forward)


Earnings History for BioTelemetry (NASDAQ:BEAT)
Earnings by Quarter for BioTelemetry (NASDAQ:BEAT)
Earnings History by Quarter for BioTelemetry (NASDAQ:BEAT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017Q1 2017$0.14$0.16$55.11 million$55.88 millionViewListenView Earnings Details
2/22/2017Q4 2016$0.18$0.23$53.75 million$53.96 millionViewListenView Earnings Details
11/2/2016Q316$0.18$0.21$52.92 million$53.10 millionViewN/AView Earnings Details
8/2/2016Q2$0.17$0.20$50.27 million$52.68 millionViewListenView Earnings Details
4/26/2016Q1$0.10$0.20$46.54 million$48.60 millionViewListenView Earnings Details
2/17/2016Q415$0.11$0.15$45.89 million$46.70 millionViewListenView Earnings Details
11/9/2015Q3$0.11$0.13$46.05 million$43.49 millionViewN/AView Earnings Details
8/6/2015Q2$0.09$0.12$45.75 million$44.81 millionViewListenView Earnings Details
5/6/2015Q115$0.02$0.06$43.80 million$43.40 millionViewListenView Earnings Details
2/19/2015Q414$0.06$0.05$43.40 million$43.70 millionViewListenView Earnings Details
10/30/2014Q214$0.01$0.06$42.00 million$43.00 millionViewListenView Earnings Details
7/31/2014Q114$0.01$0.02$40.95 million$42.70 millionViewListenView Earnings Details
5/6/2014Q413($0.02)($0.04)$38.40 million$37.16 millionViewListenView Earnings Details
2/26/2014Q313($0.04)$0.05$32.26 million$33.10 millionViewListenView Earnings Details
11/5/2013($0.05)($0.12)$32.79 million$31.90 millionViewListenView Earnings Details
7/30/2013Q2 2013$0.02$27.50 million$32.10 millionViewListenView Earnings Details
2/13/2013Q4 2012($0.09)$26.80 million$30.00 millionViewListenView Earnings Details
11/5/2012Q312($0.09)($0.08)$26.49 million$27.00 millionViewN/AView Earnings Details
8/8/2012($0.04)($0.01)ViewN/AView Earnings Details
5/8/2012($0.12)($0.10)ViewN/AView Earnings Details
2/22/2012($0.13)($0.04)ViewN/AView Earnings Details
11/8/2011($0.09)($0.21)ViewN/AView Earnings Details
8/8/2011($0.06)($0.05)ViewN/AView Earnings Details
5/3/2011($0.15)($0.02)ViewN/AView Earnings Details
2/17/2011($0.16)($0.13)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BioTelemetry (NASDAQ:BEAT)
2017 EPS Consensus Estimate: $0.81
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.20$0.20$0.20
Q2 20171$0.20$0.20$0.20
Q3 20171$0.19$0.19$0.19
Q4 20171$0.22$0.22$0.22
(Data provided by Zacks Investment Research)


Dividend History for BioTelemetry (NASDAQ:BEAT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for BioTelemetry (NASDAQ:BEAT)
Insider Ownership Percentage: 11.00%
Institutional Ownership Percentage: 84.23%
Insider Trades by Quarter for BioTelemetry (NASDAQ:BEAT)
Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)
Insider Trades by Quarter for BioTelemetry (NASDAQ:BEAT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Robert J. RubinDirectorSell15,000$28.14$422,100.00View SEC Filing  
3/20/2017Fred BroadwaySVPSell3,429$26.90$92,240.10View SEC Filing  
2/27/2017George HrenkoSVPSell126,043$25.95$3,270,815.85View SEC Filing  
2/21/2017Fred BroadwaySVPSell8,070$24.81$200,216.70View SEC Filing  
9/19/2016George HrenkoSVPSell1,061$18.50$19,628.50View SEC Filing  
9/13/2016Heather C GetzCFOSell5,866$18.23$106,937.18View SEC Filing  
9/13/2016Joseph H CapperInsiderSell26,847$18.23$489,420.81View SEC Filing  
9/13/2016Peter FerolaGeneral CounselSell4,352$18.23$79,336.96View SEC Filing  
9/9/2016Fred BroadwaySVPSell3,146$17.84$56,124.64View SEC Filing  
9/8/2016George HrenkoSVPSell3,491$18.06$63,047.46View SEC Filing  
9/8/2016Heather C GetzCFOSell2,979$18.10$53,919.90View SEC Filing  
9/8/2016Joseph H CapperInsiderSell13,632$18.10$246,739.20View SEC Filing  
9/8/2016Peter FerolaGeneral CounselSell2,210$18.10$40,001.00View SEC Filing  
9/7/2016Daniel WisniewskiSVPSell9,225$18.51$170,754.75View SEC Filing  
9/7/2016Heather C GetzCFOSell18,945$18.52$350,861.40View SEC Filing  
9/7/2016Joseph H CapperInsiderSell86,681$18.52$1,605,332.12View SEC Filing  
9/7/2016Peter FerolaGeneral CounselSell14,053$18.52$260,261.56View SEC Filing  
9/6/2016Fred BroadwaySVPSell4,662$18.28$85,221.36View SEC Filing  
9/6/2016Heather C GetzCFOSell6,686$18.29$122,286.94View SEC Filing  
9/6/2016Joseph H CapperCEOSell30,595$18.29$559,582.55View SEC Filing  
9/6/2016Peter FerolaGeneral CounselSell4,960$18.29$90,718.40View SEC Filing  
9/2/2016Fred BroadwaySVPSell4,466$18.75$83,737.50View SEC Filing  
9/2/2016Heather C GetzCFOSell6,547$18.75$122,756.25View SEC Filing  
9/2/2016Joseph H CapperCEOSell29,953$18.75$561,618.75View SEC Filing  
9/2/2016Peter FerolaGeneral CounselSell4,856$18.75$91,050.00View SEC Filing  
9/1/2016Fred BroadwaySVPSell7,525$19.25$144,856.25View SEC Filing  
9/1/2016Heather C GetzCFOSell10,408$18.59$193,484.72View SEC Filing  
9/1/2016Joseph H CapperInsiderSell47,622$18.59$885,292.98View SEC Filing  
9/1/2016Peter FerolaGeneral CounselSell7,722$18.59$143,551.98View SEC Filing  
8/30/2016Fred BroadwaySVPSell12,121$19.07$231,147.47View SEC Filing  
8/30/2016Heather C GetzCFOSell17,482$19.07$333,381.74View SEC Filing  
8/30/2016Joseph H CapperInsiderSell79,986$19.07$1,525,333.02View SEC Filing  
8/30/2016Peter FerolaGeneral CounselSell12,970$19.07$247,337.90View SEC Filing  
8/25/2016Fred BroadwaySVPSell5,877$19.16$112,603.32View SEC Filing  
8/25/2016Heather C GetzCFOSell8,477$19.16$162,419.32View SEC Filing  
8/25/2016Joseph H CapperInsiderSell38,785$19.16$743,120.60View SEC Filing  
8/25/2016Peter FerolaGeneral CounselSell6,289$19.16$120,497.24View SEC Filing  
8/24/2016George HrenkoSVPSell7,473$20.11$150,282.03View SEC Filing  
8/24/2016Heather C GetzCFOSell8,778$20.11$176,525.58View SEC Filing  
8/24/2016Joseph H CapperCEOSell40,160$20.11$807,617.60View SEC Filing  
8/24/2016Peter FerolaGeneral CounselSell6,512$20.11$130,956.32View SEC Filing  
8/23/2016George HrenkoSVPSell3,165$20.67$65,420.55View SEC Filing  
8/23/2016Heather C GetzCFOSell3,717$20.67$76,830.39View SEC Filing  
8/23/2016Joseph H CapperCEOSell17,008$20.67$351,555.36View SEC Filing  
8/23/2016Peter FerolaGeneral CounselSell2,758$20.67$57,007.86View SEC Filing  
8/22/2016George HrenkoSVPSell4,149$20.85$86,506.65View SEC Filing  
8/22/2016Heather C GetzCFOSell4,874$20.85$101,622.90View SEC Filing  
8/22/2016Joseph H CapperCEOSell22,298$20.85$464,913.30View SEC Filing  
8/22/2016Peter FerolaGeneral CounselSell3,616$20.85$75,393.60View SEC Filing  
8/19/2016Daniel WisniewskiSVPSell9,025$20.96$189,164.00View SEC Filing  
8/19/2016Heather C GetzCFOSell9,026$20.96$189,184.96View SEC Filing  
8/19/2016Joseph H CapperInsiderSell9,049$20.96$189,667.04View SEC Filing  
8/19/2016Peter FerolaGeneral CounselSell9,035$20.96$189,373.60View SEC Filing  
5/9/2014Ronald AhrensDirectorBuy6,000$7.37$44,220.00View SEC Filing  
11/12/2013Ronald AhrensDirectorBuy5,000$11.73$58,650.00View SEC Filing  
11/12/2012Ronald A AhrensDirectorBuy15,000$2.22$33,300.00View SEC Filing  
9/5/2012Joseph H CapperCEOBuy23,540$2.25$52,965.00View SEC Filing  
8/31/2012Joseph H CapperCEOBuy2,600$2.28$5,928.00View SEC Filing  
8/29/2012Joseph H CapperCEOBuy10,800$2.30$24,840.00View SEC Filing  
8/28/2012Joseph H CapperCEOBuy1,300$2.19$2,847.00View SEC Filing  
8/27/2012Joseph H CapperCEOBuy1,600$2.12$3,392.00View SEC Filing  
8/23/2012Joseph H CapperCEOBuy9,600$2.08$19,968.00View SEC Filing  
8/20/2012Joseph H CapperCEOBuy14,160$1.97$27,895.20View SEC Filing  
8/17/2012Joseph H CapperCEOBuy9,800$2.10$20,580.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for BioTelemetry (NASDAQ:BEAT)
Latest Headlines for BioTelemetry (NASDAQ:BEAT)
DateHeadline logoBioTelemetry (BEAT) Increases Price, Extends Tender Offer Period for LifeWatch AG Shares - May 26 at 2:53 AM logoBioTelemetry, Inc. Increases Tender Offer Price and Extends Offer Period for LifeWatch AG Shares - GlobeNewswire (press release) - May 24 at 8:48 PM logoBioTelemetry (BEAT) Extends Tender Offer Period for LifeWatch AG Shares - May 24 at 11:49 AM logoBioTelemetry, Inc. Increases Tender Offer Price and Extends Offer Period for LifeWatch AG Shares - May 24 at 11:49 AM logoBioTelemetry, Inc. Announces Extension of the Tender Offer Period for LifeWatch AG Shares - May 23 at 11:18 AM logoBioTelemetry, Inc. Announces Extension of the Tender Offer Period for LifeWatch AG Shares - May 23 at 11:18 AM logoBioTelemetry, Inc. (BEAT) Director Robert J. Rubin Sells 15,000 Shares - May 16 at 7:32 PM logoBioTelemetry, Inc. breached its 50 day moving average in a Bearish Manner : BEAT-US : May 15, 2017 - May 15 at 4:20 PM logoBioTelemetry, Inc. (BEAT) Given Average Recommendation of "Buy" by Brokerages - May 12 at 2:38 PM logoBioTelemetry, Inc. Announces the Start of the Tender Offer Period for LifeWatch AG Shares - May 10 at 8:53 AM logoBioTelemetry, Inc. – Value Analysis (NASDAQ:BEAT) : May 8, 2017 - May 8 at 8:46 PM logoBioTelemetry (BEAT) Receives Antitrust Clearance for Acquisition of LifeWatch AG - - May 8 at 3:46 PM logoBioTelemetry, Inc. (BEAT) to Post FY2018 Earnings of $1.45 Per Share, Gabelli Forecasts - May 8 at 12:12 PM logoBioTelemetry (BEAT) Receives Antitrust Clearance for Acquisition of LifeWatch AG - May 8 at 10:34 AM logoBuy the dip in BEAT, say analysts - Seeking Alpha - May 5 at 8:53 PM logoBioTelemetry, Inc. (BEAT) Downgraded by Zacks Investment Research - May 5 at 8:20 PM logoBioTelemetry, Inc. breached its 50 day moving average in a Bearish Manner : BEAT-US : May 5, 2017 - May 5 at 3:53 PM logoGabelli Analysts Lift Earnings Estimates for BioTelemetry, Inc. (BEAT) - May 5 at 2:24 PM logoBioTelemetry, Inc. (BEAT) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - May 4 at 9:00 PM logoBioTelemetry, Inc. Reports First Quarter 2017 Financial Results - GlobeNewswire (press release) - May 4 at 3:59 PM logoIndexes Trim Losses As Oil Stocks Sink; Did Tesla Flash A Sell Signal? - May 4 at 3:59 PM logoEdited Transcript of BEAT earnings conference call or presentation 3-May-17 9:00pm GMT - May 4 at 3:59 PM logoWhy BioTelemetry, Inc. Is Slumping 14% Today - May 4 at 2:41 PM logoBioTelemetry (BEAT) Getting Favorable Press Coverage, Analysis Shows - May 4 at 1:10 PM logoBioTelemetry, Inc. Reports First Quarter 2017 Financial Results - Nasdaq - May 3 at 8:59 PM logoBioTelemetry, Inc. Reports First Quarter 2017 Financial Results - May 3 at 8:59 PM logoBioTelemetry posts 1Q profit - May 3 at 8:59 PM logoBioTelemetry, Inc. (BEAT) Upgraded at Zacks Investment Research - May 2 at 11:14 PM logoBioTelemetry, Inc. (BEAT) to Release Earnings on Wednesday - May 1 at 1:20 PM logoBioTelemetry (BEAT) Receives Media Sentiment Rating of -0.12 - May 1 at 12:45 PM logoBioTelemetry (BEAT) Receiving Positive Press Coverage, Study Finds - April 26 at 5:24 PM logoETFs with exposure to BioTelemetry, Inc. : April 26, 2017 - April 26 at 4:12 PM logoBioTelemetry, Inc. to Release First Quarter 2017 Earnings Results on May 3, 2017 - April 26 at 11:38 AM logoBioTelemetry, Inc. (BEAT) Downgraded by Zacks Investment Research to "Hold" - April 25 at 9:52 PM logoBioTelemetry (BEAT) Issues Prospectus for Public Tender Offer to Acquire LifeWatch AG - - April 25 at 3:46 PM logoBioTelemetry, Inc. Issues Prospectus for Public Tender Offer to Acquire LifeWatch AG - April 25 at 12:39 PM logoSomewhat Critical Media Coverage Extremely Likely to Affect BioTelemetry (BEAT) Share Price - April 23 at 1:23 PM logoBioTelemetry, Inc. (BEAT) Set to Announce Quarterly Earnings on Monday - April 21 at 10:00 PM logo$55.31 Million in Sales Expected for BioTelemetry, Inc. (BEAT) This Quarter - April 21 at 4:30 PM logo$0.17 Earnings Per Share Expected for BioTelemetry, Inc. (BEAT) This Quarter - April 19 at 7:34 AM logoBioTelemetry (BEAT) Earns Daily News Sentiment Rating of 0.20 - April 17 at 4:12 PM logoBioTelemetry, Inc. (BEAT) Given Consensus Recommendation of "Buy" by Brokerages - April 17 at 3:08 PM logoBioTelemetry, Inc. (BEAT) Sees Large Increase in Short Interest - April 17 at 12:10 PM logoWill BioTelemetry (BEAT) Continue to Surge Higher? - Yahoo Finance - April 13 at 9:03 PM logoBioTelemetry (BEAT) Earns News Impact Score of 0.19 - April 13 at 5:52 PM logoWill BioTelemetry (BEAT) Continue to Surge Higher? - April 12 at 11:28 AM logoBioTelemetry Inc. (BEAT) Rose To A New High After LifeWatch Acquisition - RTT News - April 11 at 3:54 PM logoBioTelemetry (BEAT) Shows Strength: Stock Moves 8.8% Higher - April 11 at 3:54 PM logoBioTelemetry, Inc. (BEAT) Price Target Raised to $37.00 at Dougherty & Co - April 11 at 12:53 PM logoBioTelemetry Inc. (BEAT) Has Broken Out To A New High After Acquisition - April 10 at 11:02 AM



BioTelemetry (BEAT) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by Staff